The autoimmune ecology

Frontiers in Immunology

Volumn 7, Issue APR, 2016, Pages

  Anaya, Juan Manuel ^a   Ramirez Santana, Carolina ^a   Alzate, Maria A ^a   Molano Gonzalez, Nicolas ^a   Rojas Villarraga, Adriana ^a  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

Author keywords

Autoimmune disease; Ecology; Environment; Personalized medicine; Polyautoimmunity

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ALCOHOL; B CELL ACTIVATING FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 8; ORGANIC SOLVENT; PROSTAGLANDIN; SEX HORMONE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; VACCINE; VITAMIN D;

ALCOHOL CONSUMPTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CLINICAL TRIAL (TOPIC); COFFEE; DISEASE COURSE; DNA METHYLATION; ECOLOGY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENDER; GENE EXPRESSION; GENETICS; HUMAN; IMMUNE RESPONSE; INFECTION; INNATE IMMUNITY; META ANALYSIS (TOPIC); MICROFLORA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SMOKING; SOCIAL STATUS; SYSTEMATIC REVIEW (TOPIC); T LYMPHOCYTE;

EID: 84966716018     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00139     Document Type: Review

References (267)

1. Tarkowski S. Human ecology and public health. Eur J Public Health. (2009) 19(5):447. doi:10.1093/eurpub/ckp152
2. Lawrence RJ. Human Ecology. Culture, Civilization and Human Society. Geneva: Encyclopedia of Life Support Systems (EOLSS) (2000). p. 1-5
3. Odum E, Barrett G. The Scope of Ecology. Fundamentals of Ecology. Boston, MA, United States: Cengage Learning (2004). p. 1-16
4. Rojas-Villarraga A, Castellanos-de la Hoz J, Perez-Fernandez OM, Amaya-Amaya J, Franco J-S, Anaya JM. Autoimmune Ecology. Autoimmunity: From Bench to Bedside. Bogotá: El Rosario University Press (2013). p. 321-41
5. Dyball R. Human Ecology. Understanding Human Ecology: A systems approach to sustainability. Great Barrington, MA, United States: Berkshire Publishing Group (2012). p. 184-8
6. Caldwell DE. Post-modern ecology-is the environment the organism? Environ Microbiol (1999) 1(4):279-81. doi:10.1046/j.1462-2920.1999.00048.x
7. Jackson RJ. Environment meets health, again. Science (2007) 315(5817):1337. doi:10.1126/science.1141968
8. Green L, Fryer GE, Yawn BP, Lanier D, Dovey SM. The ecology of medical care revisited. N Engl J Med (2001) 344(26):2021-5. doi:10.1056/NEJM200106283442611
9. Fryer GE, Green L, Dovey SM, Yawn BP, Phillips RL, Lanier D. Variation in the ecology of medical care. Ann Fam Med (2003) 1(2):81-9. doi:10.1370/afm.52
10. Parks C, Miller F, Pollard K, Selmi C, Germolec D, Joyce K, et al. Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. Int J Mol Sci (2014) 15(8):14269-97. doi:10.3390/ijms150814269
11. Miller FW, Alfredsson L, Costenbader KH, Kamen DL, Nelson LM, Norris JM, et al. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmun (2012) 39(4):259-71. doi:10.1016/j.jaut.2012.05.002
12. Castiblanco J, Anaya JM. The nature and nurture of common autoimmunity. Ann N Y Acad Sci (2007) 1109:1-8. doi:10.1196/annals.1398.001
13. Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJ, Furman D, et al. Variation in the human immune system is largely driven by non-heritable influences. Cell (2015) 160(1-2):37-47. doi:10.1016/j.cell.2014.12.020
14. Anaya J-M. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev (2012) 11(11):781-4. doi:10.1016/j.autrev.2012.02.002
15. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC, United States: National Academies Press (US) (2011)
16. Wild CP. The exposome: from concept to utility. Int J Epidemiol (2012) 41(1):24-32. doi:10.1093/ije/dyr236
17. Rappaport SM, Barupal DK, Wishart D, Vineis P, Scalbert A. The blood exposome and its role in discovering causes of disease. Environ Health Perspect (2014) 122(8):769-74. doi:10.1289/ehp.1308015
18. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun (2009) 33(3-4):197-207. doi:10.1016/j.jaut.2009.09.008
19. Anaya JM, Gómez LM, Castiblanco J. Is there a common genetic basis for autoimmune diseases? Clin Dev Immunol (2006) 13(2-4):185-95. doi:10.1080/17402520600876762
20. Cho J, Gregersen P. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med (2011) 365(17):1612-23. doi:10.1056/NEJMra1100030
21. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature (2009) 461(7265):747-53. doi:10.1038/nature08494
22. Ellis JA, Kemp AS, Ponsonby AL. Gene-environment interaction in autoimmune disease. Expert Rev Mol Med (2014) 16:e4. doi:10.1017/erm.2014.5
23. Boyce WT, Kobor MS. Development and the epigenome: the "synapse" of gene-environment interplay. Dev Sci (2015) 18(1):1-23. doi:10.1111/desc.12282
24. Miller F, Hess E, Clauw D, Hertzman P, Pincus T, Silver R, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum (2000) 43(2):243-9. doi:10.1002/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K
25. Miller FW, Pollard KM, Parks CG, Germolec DR, Leung PSC, Selmi C, et al. Criteria for environmentally associated autoimmune diseases. J Autoimmun (2012) 39(4):253-8. doi:10.1016/j.jaut.2012.05.001
26. Hill A. The environment and disease: association or causation? Proc R Soc Med (1965) 58:295-300
27. Sabroe I, Read RC, Whyte MK, Dockrell DH, Vogel SN, Dower SK. Toll-like receptors in health and disease: complex questions remain. J Immunol (2003) 171(4):1630-5. doi:10.4049/jimmunol.171.4.1630
28. O'Neill LA. The interleukin-1 receptor/toll-like receptor superfamily: 10 Years of progress. Immunol Rev (2008) 226(1):10-8. doi:10.1111/j.1600-065X.2008.00701.x
29. Liu Y, Yin H, Zhao M, Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol (2013) 47(2):136-47. doi:10.1007/s12016-013-8402-y
30. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell (2006) 124(4):783-801. doi:10.1016/j.cell.2006.02.015
31. Gianchecchi E, Fierabracci A. Gene/environment interactions in the pathogenesis of autoimmunity: new insights on the role of toll-like receptors. Autoimmun Rev (2015) 14(11):971-83. doi:10.1016/j.autrev.2015.07.006
32. Hurst J, von Landenberg P. Toll-like receptors and autoimmunity. Autoimmun Rev (2008) 7(3):204-8. doi:10.1016/j.autrev.2007.11.006
33. Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med (2014) 20:138-46. doi:10.2119/molmed.2013.00164
34. Wähämaa H, Schierbeck H, Hreggvidsdottir HS, Palmblad K, Aveberger AC, Andersson U, et al. High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res Ther (2011) 13(4):R136. doi:10.1186/ar3450
35. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol (2011) 11(12):807-22. doi:10.1038/nri3095
36. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med (2007) 204(12):2899-912. doi:10.1084/jem.20071030
37. Saal JG, Steidle M, Einsele H, Müller CA, Fritz P, Zacher J. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int (1992) 12(4):147-51. doi:10.1007/BF00274934
38. Saal JG, Krimmel M, Steidle M, Gerneth F, Wagner S, Fritz P, et al. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis Rheum (1999) 42(7):1485-96. doi:10.1002/1529-0131(199907)42:7<1485::AID-ANR24>3.0.CO;2-7
39. Herrmann I, Kellert M, Schmidt H, Mildner A, Hanisch UK, Bruck W, et al. Streptococcus pneumoniae Infection aggravates experimental autoimmune encephalomyelitis via toll-like receptor 2. Infect Immun (2006) 74(8):4841-8. doi:10.1128/IAI.00026-06
40. Schrijver IA, Melief MJ, Tak PP, Hazenberg MP, Laman JD. Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines. Arthritis Rheum (2000) 43(10):2160-8. doi:10.1002/1529-0131(200010)43:10<2160::AID-ANR3>3.0.CO;2-T
41. Marta M, Andersson A, Isaksson M, Kämpe O, Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol (2008) 38(2):565-75. doi:10.1002/eji.200737187
42. Frasnelli ME, Tarussio D, Chobaz-Péclat V, Busso N, So A. TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res Ther (2005) 7(2):R370-9. doi:10.1186/ar1494
43. Ronaghy A, Prakken B, Takabayashi K, Firestein G, Boyle D, Zvailfler N, et al. Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J Immunol (2002) 168(1):51-6. doi:10.4049/jimmunol.168.1.51
44. Shoenfeld Y, Agmon-Levin N. "ASIA"-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun (2011) 36(1):4-8. doi:10.1016/j.jaut.2010.07.003
45. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun (2013) 47:1-16. doi:10.1016/j.jaut.2013.10.004
46. Demento S, Eisenbarth S, Foellmer H, Platt C, Caplan M, Mark-Saltzman W, et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine (2009) 27(23):3013-21. doi:10.1016/j.vaccine.2009.03.034
47. Vera-Lastra O, Medina G, Cruz-Dominguez Mdel P, Jara LJ, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol (2013) 9(4):361-73. doi:10.1586/eci.13.2
48. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, Jung S, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med (2008) 205(4):869-82. doi:10.1084/jem.20071087
49. Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun (2001) 69(2):1151-9. doi:10.1128/IAI.69.2.1151-1159.2001
50. Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med (2011) 17(8):996-1002. doi:10.1038/nm.2403
51. Kuroda Y, Akaogi J, Nacionales DC, Wasdo SC, Szabo NJ, Reeves WH, et al. Distinctive patterns of autoimmune response induced by different types of mineral oil. Toxicol Sci (2004) 78(2):222-8. doi:10.1093/toxsci/kfh063
52. Vera-Lastra O, Medina G, Cruz-Dominguez Mdel P, Ramirez P, Gayosso-Rivera JA, Anduaga-Dominguez H, et al. Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld's syndrome). Lupus (2012) 21(2):128-35. doi:10.1177/0961203311429317
53. Agmon-Levin N, Hughes GC, Shoenfeld Y. The spectrum of ASIA: "autoimmune (auto-inflammatory) syndrome induced by adjuvants". Lupus (2012) 21(2):118-20. doi:10.1177/0961203311429316
54. Wolfram D, Rabensteiner E, Grundtman C, Böck G, Mayerl C, Parson W, et al. T regulatory cells and TH17 cells in peri-silicone implant capsular fibrosis. Plast Reconstr Surg (2012) 129(2):327e-37e. doi:10.1097/PRS.0b013e31823aeacf
55. Bar-Meir E, Teuber SS, Lin HC, Alosacie I, Goddard G, Terybery J, et al. Multiple autoantibodies in patients with silicone breast implants. J Autoimmun (1995) 8(2):267-77. doi:10.1006/jaut.1995.0020
56. Schaefer CJ, Whalen JD, Knapp T, Wooley PH. The influence of silicone implantation on type II collagen-induced arthritis in mice. Arthritis Rheum (1997) 40(6):1064-72. doi:10.1002/art.1780400611
57. Schaefer CJ, Wooley PH. The influence of silicone implantation on murine lupus in MRL lpr/lpr mice. J Rheumatol (1999) 26(10):2215-21
58. Richez C, Blanco P, Rifkin I, Moreau JF, Schaeverbeke T. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine (2011) 78(2):124-30. doi:10.1016/j.jbspin.2010.09.005
59. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum (2006) 54(11):3601-11. doi:10.1002/art.22197
60. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med (2008) 358(9):929-39. doi:10.1056/NEJMra071297
61. Hoffmann MH, Skriner K, Herman S, Baumann C, Steiner CW, Ospelt C, et al. Nucleic acid-stimulated antigen-presenting cells trigger T cells to induce disease in a rat transfer model of inflammatory arthritis. J Autoimmun (2011) 36(3-4):288-300. doi:10.1016/j.jaut.2011.02.007
62. Theofilopoulos AN, Gonzalez-Quintial R, Lawson BR, Koh YT, Stern ME, Kono DH, et al. Sensors of the innate immune system: their link to rheumatic diseases. Nat Rev Rheumatol (2010) 6(3):146-56. doi:10.1038/nrrheum.2009.278
63. Dörner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther (2009) 11(5):247. doi:10.1186/ar2780
64. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature (2005) 435(7042):590-7. doi:10.1038/nature03724
65. Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. Immunity (2008) 28(1):18-28. doi:10.1016/j.immuni.2007.12.004
66. Selmi C, Leung PS, Sherr DH, Diaz M, Nyland JF, Monestier M, et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J Autoimmun (2012) 39(4):272-84. doi:10.1016/j.jaut.2012.05.007
67. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 46(10):2673-7. doi:10.1002/art.10541
68. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol (2005) 17(5):550-7. doi:10.1097/01.bor.0000172798.26249.fc
69. Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med (1994) 180(4):1295-306. doi:10.1084/jem.180.4.1295
70. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 350(25):2572-81. doi:10.1056/NEJMoa032534
71. Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest (2007) 117(12):3857-67. doi:10.1172/JCI32405
72. Antel J, Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol (2006) 180(1-2):3-8. doi:10.1016/j.jneuroim.2006.06.032
73. Brink R. The imperfect control of self-reactive germinal center B cells. Curr Opin Immunol (2014) 28:97-101. doi:10.1016/j.coi.2014.03.001
74. Harris D, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol (2000) 1(6):475-82. doi:10.1038/82717
75. Wong FS, Wen L, Tang M, Ramanathan M, Visintin I, Daugherty J, et al. Investigation of the role of B-cell in Type 1 diabetes in the NOD mouse. Diabetes (2004) 53(10):2581-7. doi:10.2337/diabetes.53.10.2581
76. Galarza C, Valencia D, Tobón GJ, Zurita L, Mantilla RD, Pineda-Tamayo R, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol (2008) 34(1):124-8. doi:10.1007/s12016-007-8028-z
77. Strickland F, Hewagama A, Lu Q, Wu A, Hinderer R, Webb R, et al. Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus. J Autoimmun (2012) 38(2-3):J135-43. doi:10.1016/j.jaut.2011.11.001
78. Gubbels Bupp MR, Jørgensen TN, Kotzin BL. Identification of candidate genes that influence sex hormone-dependent disease phenotypes in mouse lupus. Genes Immun (2008) 9(1):47-56. doi:10.1038/sj.gene.6364447
79. Lu Q, Wu A, Tesmer L, Ray D, Yousif N, Richardson B. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol (2007) 179(9):6352-8. doi:10.4049/jimmunol.179.9.6352
80. Zhou Y, Yuan J, Pan Y, Fei Y, Qiu X, Hu N, et al. T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin Immunol (2009) 132(3):362-70. doi:10.1016/j.clim.2009.05.011
81. Luckey D, Medina K, Taneja V. B cells as effectors and regulators of sex-biased arthritis. Autoimmunity (2012) 45(5):364-76. doi:10.3109/08916934.2012.665528
82. Mustafa A, Holladay SD, Witonsky S, Zimmerman K, Reilly CM, Sponenberg DP, et al. Gestational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin disrupts B-cell lymphopoiesis and exacerbates autoimmune disease in 24-week-old SNF1 mice. Toxicol Sci (2009) 112(1):133-43. doi:10.1093/toxsci/kfp177
83. Abedi-Valugerdi M. Mercury and silver induce B cell activation and anti-nucleolar autoantibody production in outbred mouse stocks: are environmental factors more important than the susceptibility genes in connection with autoimmunity? Clin Exp Immunol (2008) 155(1):117-24. doi:10.1111/j.1365-2249.2008.03801.x
84. Silbergeld EK, Silva IA, Nyland JF. Mercury and autoimmunity: implications for occupational and environmental health. Toxicol Appl Pharmacol (2005) 207(2 Suppl):282-92. doi:10.1016/j.taap.2004.11.035
85. Ferraccioli G, Tolusso B. Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. Autoimmun Rev (2007) 7(2):109-13. doi:10.1016/j.autrev.2007.02.013
86. Rothe K, Quandt D, Schubert K, Rossol M, Klingner M, Jasinski-Bergner S, et al. Latent cytomegalovirus infection in rheumatoid arthritis and increased frequencies of cytolytic LIR-1+CD8+ T cells. Arthritis Rheumatol (2016) 68(2):337-46. doi:10.1002/art.39331
87. Singh RP, Hasan S, Sharma S, Nagra S, Yamaguchi DT, Wong DT, et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev (2014) 13(12):1174-81. doi:10.1016/j.autrev.2014.08.019
88. Acosta-Rodriguez E, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol (2007) 8(9):942-9. doi:10.1038/ni1496
89. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature (2008) 453(7191):106-9. doi:10.1038/nature06881
90. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 453(7191):65-71. doi:10.1038/nature06880
91. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A (2008) 105(28):9721-6. doi:10.1073/pnas.0804231105
92. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun (2010) 34(3):J258-65. doi:10.1016/j.jaut.2009.12.003
93. Yu H, Yang YH, Rajaiah R, Moudgil KD. Nicotine-induced differential modulation of autoimmune arthritis in the Lewis rat involves changes in interleukin-17 and anti-cyclic citrullinated peptide antibodies. Arthritis Rheum (2011) 63(4):981-91. doi:10.1002/art.30219
94. Hagiwara E, Takahashi KI, Okubo T, Ohno S, Ueda A, Aoki A, et al. Cigarette smoking depletes cells spontaneously secreting Th(1) cytokines in the human airway. Cytokine (2001) 14(2):121-6. doi:10.1006/cyto.2001.0860
95. Muniz Caldas CA, Freire de Carvalho J. The role of environmental factors in the pathogenesis of non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol (2012) 26(1):5-11. doi:10.1016/j.berh.2012.01.010
96. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7(9):937-45. doi:10.1038/ni1376
97. Quintana FJ, Weiner HL. Environmental control of Th17 differentiation. Eur J Immunol (2009) 39(3):655-7. doi:10.1002/eji.200839198
98. Ho P, Steinman L. The aryl hydrocarbon receptor: a regulator of Th17 and Treg cell development in disease. Cell Res (2008) 18:605-8. doi:10.1038/cr.2008.63
99. Ishimaru N, Takagi A, Kohashi M, Yamada A, Arakaki R, Kanno J, et al. Neonatal exposure to low-dose 2,3,7,8-tetrachlorodibenzo-p-dioxin causes autoimmunity due to the disruption of T cell tolerance. J Immunol (2009) 182(10):6576-86. doi:10.4049/jimmunol.0802289
100. Caricchio R, McPhie L, Cohen PL. Ultraviolet B radiation-induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J Immunol (2003) 171(11):5778-86. doi:10.4049/jimmunol.171.11.5778
101. Mak A, Tay S. Environmental factors, toxicants and systemic lupus erythematosus. Int J Mol Sci (2014) 15(9):16043-56. doi:10.3390/ijms150916043
102. Saeki T, Fujita N, Kourakata H, Yamazaki H, Miyamura S. Two cases of hypertrophic pachymeningitis associated with myeloperoxidase antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive pulmonary silicosis in tunnel workers. Clin Rheumatol (2004) 23(1):76-80. doi:10.1007/s10067-003-0815-1
103. Lee S, Hayashi H, Maeda M, Chen Y, Matsuzaki H, Takei-Kumagai N, et al. Environmental factors producing autoimmune dysregulation-chronic activation of T cells caused by silica exposure. Immunobiology (2012) 217(7):743-8. doi:10.1016/j.imbio.2011.12.009
104. Otsuki T, Hayashi H, Nishimura Y, Hyodo F, Maeda M, Kumagai N, et al. Dysregulation of autoimmunity caused by silica exposure and alteration of Fas-mediated apoptosis in T lymphocytes derived from silicosis patients. Int J Immunopathol Pharmacol (2011) 24(1 Suppl):11S-16S
105. Zavala-Cerna MG, Martínez-García EA, Torres-Bugarín O, Rubio-Jurado B, Riebeling C, Nava A. The clinical significance of posttranslational modification of autoantigens. Clin Rev Allergy Immunol (2014) 47(1):73-90. doi:10.1007/s12016-014-8424-0
106. Harel-Meir M, Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol (2007) 3(12):707-15. doi:10.1038/ncprheum0655
107. Holers VM. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr Opin Immunol (2013) 25(6):728-35. doi:10.1016/j.coi.2013.09.018
108. Serra-Bonett N, Rodríguez MA. The swollen joint, the thickened artery, and the smoking gun: tobacco exposure, citrullination and rheumatoid arthritis. Rheumatol Int (2011) 31(5):567-72. doi:10.1007/s00296-010-1644-6
109. Rombouts Y, Willemze A, van Beers JJ, Shi J, Kerkman PF, van Toorn L, et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann Rheum Dis (2016) 75(3):578-85. doi:10.1136/annrheumdis-2014-206598
110. Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Méchin MC, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum (2007) 56(11):3541-53. doi:10.1002/art.22983
111. Kinloch A, Lundberg K, Wait R, Wegner N, Ngee HL, Zendman AJ, et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum (2008) 58(8):2287-95. doi:10.1002/art.23618
112. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet (2003) 34(4):395-402. doi:10.1038/ng1206
113. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum (2006) 54(1):38-46. doi:10.1002/art.21575
114. Hill J, Southwood S, Sette A, Jevnikar A, Bell D, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis associated HLA-DRB1*0401 MHC class II molecule. J Immunol (2003) 171(2):538-41. doi:10.4049/jimmunol.171.2.538
115. Mattey DL, Hutchinson D, Dawes PT, Nixon NB, Clarke S, Fisher J, et al. Smoking and disease severity in rheumatoid arthritis: association with polymorphism at the glutathione S-transferase M1 locus. Arthritis Rheum (2002) 46(3):640-6. doi:10.1002/art.10174
116. Lim SY, Ghosh SK. Autoreactive responses to environmental factors: 3. Mouse strain-specific differences in induction and regulation of anti-DNA antibody responses due to phthalate-isomers. J Autoimmun (2005) 25(1):33-45. doi:10.1016/j.jaut.2005.04.002
117. Jeffries MA, Sawalha AH. Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve? Expert Rev Clin Immunol (2015) 11(1):45-58. doi:10.1586/1744666X.2015.994507
118. Somers EC, Richardson BC. Environmental exposures, epigenetic changes and the risk of lupus. Lupus (2014) 23(6):568-76. doi:10.1177/0961203313499419
119. Deng Y, Tsao BP. Advances in lupus genetics and epigenetics. Curr Opin Rheumatol (2014) 26(5):482-92. doi:10.1097/BOR.0000000000000086
120. Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res (2014) 2014:419029. doi:10.1155/2014/419029
121. Gorelik G, Richardson B. Aberrant T cell ERK pathway signaling and chromatin structure in lupus. Autoimmun Rev (2009) 8(3):196-8. doi:10.1016/j.autrev.2008.07.043
122. Zhang Y, Zhao M, Sawalha AH, Richardson B, Lu Q. Impaired DNA methylation and its mechanisms in CD4+T cells of systemic lupus erythematosus. J Autoimmun (2013) 41:92-9. doi:10.1016/j.jaut.2013.01.005
123. Gorelik G, Fang JY, Wu A, Sawalha AH, Richardson B. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol (2007) 179(8):5553-63. doi:10.4049/jimmunol.179.8.5553
124. Denny MF, Chandaroy P, Killen PD, Caricchio R, Lewis EE, Richardson BC, et al. Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol (2006) 176(4):2095-104. doi:10.4049/jimmunol.176.4.2095
125. Lu Q, Kaplan M, Ray D, Ray D, Zacharek S, Gutsch D, et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum (2002) 46(5):1282-91. doi:10.1002/art.10234
126. Li Y, Zhao M, Yin H, Gao F, Wu X, Luo Y, et al. Overexpression of the growth arrest and DNA damage-induced 45a gene contributes to autoimmunity by promoting DNA demethylation in lupus T cells. Arthritis Rheum (2010) 62(5):1438-47. doi:10.1002/art.27363
127. Perl A. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol (2013) 9(11):674-86. doi:10.1038/nrrheum.2013.147
128. Kosiewicz MM, Zirnheld AL, Alard P. Gut microbiota, immunity, and disease: a complex relationship. Front Microbiol (2011) 2:180. doi:10.3389/fmicb.2011.00180
129. Kranich J, Maslowski KM, Mackay CR. Commensal flora and the regulation of inflammatory and autoimmune responses. Semin Immunol (2011) 23(2):139-45. doi:10.1016/j.smim.2011.01.011
130. Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe (2012) 12(4):496-508. doi:10.1016/j.chom.2012.09.009
131. Blander JM, Torchinsky MB, Campisi L. Revisiting the old link between infection and autoimmune disease with commensals and T helper 17 cells. Immunol Res (2012) 54(1-3):50-68. doi:10.1007/s12026-012-8311-9
132. Proal AD, Albert PJ, Marshall TG. The human microbiome and autoimmunity. Curr Opin Rheumatol (2013) 25(2):234-40. doi:10.1097/BOR.0b013e32835cedbf
133. Devereux G. The increase in the prevalence of asthma and allergy: food for thought. Nat Rev Immunol (2006) 6(11):869-74. doi:10.1038/nri1958
134. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med (2009) 1(6):6ra14. doi:10.1126/scitranslmed.3000322
135. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet (2012) 13(4):260-70. doi:10.1038/nrg3182
136. Arango MT, Shoenfeld Y, Cervera R, Anaya JM. Infection and Autoimmune Diseases. Autoimmunity: From Bench to Bedside. Bogotá: El Rosario University Press (2013). p. 303-20
137. Morgan XC, Huttenhower C. Chapter 12: human microbiome analysis. PLoS Comput Biol (2012) 8(12):e1002808. doi:10.1371/journal.pcbi.1002808
138. Morgan XC, Segata N, Huttenhower C. Biodiversity and functional genomics in the human microbiome. Trends Genet (2013) 29(1):51-8. doi:10.1016/j.tig.2012.09.005
139. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature (2007) 449(7164):804-10. doi:10.1038/nature06244
140. Gosalbes MJ, Abellan JJ, Durbán A, Pérez-Cobas AE, Latorre A, Moya A. Metagenomics of human microbiome: beyond 16s rDNA. Clin Microbiol Infect (2012) 18(Suppl 4):47-9. doi:10.1111/j.1469-0691.2012.03865.x
141. Thomas T, Gilbert J, Meyer F. Metagenomics-a guide from sampling to data analysis. Microb Inform Exp (2012) 2(1):3. doi:10.1186/2042-5783-2-3
142. Smyk D, Rigopoulou EI, Baum H, Burroughs AK, Vergani D, Bogdanos DP. Autoimmunity and environment: am I at risk? Clin Rev Allergy Immunol (2012) 42(2):199-212. doi:10.1007/s12016-011-8259-x
143. Homer N, Merriman B, Nelson SF. BFAST: an alignment tool for large scale genome resequencing. PLoS One (2009) 4(11):e7767. doi:10.1371/journal.pone.0007767
144. Schmieder R, Edwards R. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. PLoS One (2011) 6(3):e17288. doi:10.1371/journal.pone.0017288
145. Cárdenas-Roldán J, Rojas-Villarraga A, Anaya JM. How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med (2013) 11:73. doi:10.1186/1741-7015-11-73
146. Anaya JM, Corena R, Castiblanco J, Rojas-Villarraga A, Shoenfeld Y. The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol (2007) 3(4):623-35. doi:10.1586/1744666X.3.4.623
147. Vessey MP, Villard-Mackintosh L, Yeates D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception (1987) 35(5):457-64. doi:10.1016/0010-7824(87)90082-5
148. Davidson C, Brooks AG, Bacon PA. Lung function in rheumatoid arthritis. A clinic survey. Ann Rheum Dis (1974) 33(4):293-7. doi:10.1136/ard.33.4.293
149. Lewis D, Capell HA, McNeil CJ, Smith WE, Brown DH. Cigarette smoking and the clinical outcome of gold therapy in rheumatoid arthritis. J Rheumatol (1984) 11(1):111-2
150. Hernández-Avila M, Liang MH, Willett WC, Stampfer MJ, Colditz GA, Rosner B, et al. Reproductive factors, smoking, and the risk for rheumatoid arthritis. Epidemiology (1990) 1(4):285-91. doi:10.1097/00001648-199007000-00005
151. Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum (1997) 40(11):1955-61. doi:10.1002/art.1780401106
152. Hutchinson D, Shepstone L, Moots R, Lear JT, Lynch MP. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis (2001) 60(3):223-7. doi:10.1136/ard.60.3.223
153. Krishnan E. Smoking, gender and rheumatoid arthritis-epidemiological clues to etiology. Results from the behavioral risk factor surveillance system. Joint Bone Spine (2003) 70(6):496-502. doi:10.1016/S1297-319X(03)00141-6
154. Criswell LA, Merlino LA, Cerhan JR, Mikuls TR, Mudano AS, Burma M, et al. Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa women's health study. Am J Med (2002) 112(6):465-71. doi:10.1016/S0002-9343(02)01051-3
155. Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M, et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) (2006) 45(6):734-40. doi:10.1093/rheumatology/kei240
156. Oliveira RD, Junta CM, Oliveira FR, Silva LM, Donadi EA, Louzada-Junior P. Share epitope, citrullinated cyclic peptide antibodies and smoking in Brazilian rheumatoid arthritis patients. Clin Rev Allergy Immunol (2008) 34(1):32-5. doi:10.1007/s12016-007-8017-2
157. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther (2006) 8(4):R133. doi:10.1186/ar2022
158. Söderlin MK, Petersson IF, Bergman S, Svensson B. Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA. Scand J Rheumatol (2011) 40(4):249-55. doi:10.3109/03009742.2010.541495
159. Harrison BJ, Silman AJ, Wiles NJ, Scott DG, Symmons DP. The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum (2001) 44(2):323-30. doi:10.1002/1529-0131(200102)44:2<323::AID-ANR49>3.0.CO;2-C
160. Westhoff G, Rau R, Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology (Oxford) (2008) 47(6):849-54. doi:10.1093/rheumatology/ken057
161. Di Giuseppe D, Discacciati A, Orsini N, Wolk A. Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis. Arthritis Res Ther (2014) 16(2):R61. doi:10.1186/ar4498
162. Castellanos-de la Hoz J, Amaya-Amaya J, Molano-González N, Gutiérrez-Infante F, Anaya JM, Rojas-Villarraga A. The influence of cigarette smoking on disease activity and joint erosions in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis (2013) 72(Suppl 3):387. doi:10.1136/annrheumdis-2013-eular.1182
163. Costenbader KH, Kim DJ, Peerzada J, Lockman S, Nobles-Knight D, Petri M, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum (2004) 50(3):849-57. doi:10.1002/art.20049
164. Freemer M, King T, Criswell L. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis (2006) 65(5):581-4. doi:10.1136/ard.2005.039438
165. Ghaussy NO, Sibbitt W, Bankhurst AD, Qualls CR. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol (2003) 30(6):1215-21
166. Amaya-Amaya J, Sarmiento-Monroy JC, Caro-Moreno J, Molano-González N, Mantilla RD, Rojas-Villarraga A, et al. Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. Autoimmune Dis (2013) 2013:794383. doi:10.1155/2013/794383
167. Perez-Fernandez OM, Amaya-Amaya J, Molano-González N, Mantilla RD, Rojas-Villarraga A, Anaya JM. Factors associated with lupus nephritis in a highly admixed population. Ann Rheum Dis (2013) 72(Suppl 3):911. doi:10.1136/annrheumdis-2013-eular.2727
168. Ramagopalan SV, Lee JD, Yee IM, Guimond C, Traboulsee AL, Ebers GC, et al. Association of smoking with risk of multiple sclerosis: a population-based study. J Neurol (2013) 260(7):1778-81. doi:10.1007/s00415-013-6873-7
169. Sundström P, Nyström L. Smoking worsens the prognosis in multiple sclerosis. Mult Scler (2008) 14(8):1031-5. doi:10.1177/1352458508093615
170. Vestergaard P. Smoking and thyroid disorders-a meta-analysis. Eur J Endocrinol (2002) 146(2):153-61. doi:10.1530/eje.0.1460153
171. Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology (2001) 33(1):16-21. doi:10.1053/jhep.2001.21165
172. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 42(5):1194-202. doi:10.1002/hep.20907
173. Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OF. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology (2000) 31(5):1055-60. doi:10.1053/he.2000.7050
174. Zein CO, Beatty K, Post AB, Logan L, Debanne S, McCullough AJ. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: a cross validated retrospective assessment. Hepatology (2006) 44(6):1564-71. doi:10.1002/hep.21423
175. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis (2010) 69(1):70-81. doi:10.1136/ard.2008.096487
176. Hazes JM, Dijkmans BA, Vandenbroucke JP, de Vries RR, Cats A. Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption. Ann Rheum Dis (1990) 49(12):980-2. doi:10.1136/ard.49.12.980
177. Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology (1994) 5(5):525-32
178. Källberg H, Jacobsen S, Bengtsson C, Pedersen M, Padyukov L, Garred P, et al. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum Dis (2009) 68(2):222-7. doi:10.1136/ard.2007.086314
179. Kiyohara C, Washio M, Horiuchi T, Asami T, Ide S, Atsumi T, et al. Cigarette smoking, alcohol consumption, and risk of systemic lupus erythematosus: a case-control study in a Japanese population. J Rheumatol (2012) 39(7):1363-70. doi:10.3899/jrheum.111609
180. Bengtsson AA, Rylander L, Hagmar L, Nived O, Sturfelt G. Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden. Rheumatology (Oxford) (2002) 41(5):563-71. doi:10.1093/rheumatology/41.5.563
181. Sundström B, Johansson I, Rantapää-Dahlqvist S. Diet and alcohol as risk factors for rheumatoid arthritis: a nested case-control study. Rheumatol Int (2015) 35(3):533-9. doi:10.1007/s00296-014-3185-x
182. Takvorian SU, Merola JF, Costenbader KH. Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus. Lupus (2014) 23(6):537-44. doi:10.1177/0961203313501400
183. Formica MK, Palmer JR, Rosenberg L, McAlindon TE. Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black women's health study. J Rheumatol (2003) 30(6):1222-6
184. Lu B, Solomon DH, Costenbader KH, Karlson EW. Alcohol consumption and risk of incident rheumatoid arthritis in women: a prospective study. Arthritis Rheumatol (2014) 66(8):1998-2005. doi:10.1002/art.38634
185. Di Giuseppe D, Alfredsson L, Bottai M, Askling J, Wolk A. Long term alcohol intake and risk of rheumatoid arthritis in women: a population based cohort study. BMJ (2012) 345:e4230. doi:10.1136/bmj.e4230
186. Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP. The protective effect of alcohol on developing rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (2013) 52(5):856-67. doi:10.1093/rheumatology/kes376
187. Jin Z, Xiang C, Cai Q, Wei X, He J. Alcohol consumption as a preventive factor for developing rheumatoid arthritis: a dose-response meta-analysis of prospective studies. Ann Rheum Dis (2014) 73(11):1962-7. doi:10.1136/annrheumdis-2013-203323
188. Wang J, Pan H-F, Ye D-Q, Su H, Li X-P. Moderate alcohol drinking might be protective for systemic lupus erythematosus: a systematic review and meta-analysis. Clin Rheumatol (2008) 27(12):1557-63. doi:10.1007/s10067-008-1004-z
189. Lee YH, Bae SC, Song GG. Coffee or tea consumption and the risk of rheumatoid arthritis: a meta-analysis. Clin Rheumatol (2014) 33(11):1575-83. doi:10.1007/s10067-014-2631-1
190. Benito-Garcia E, Heller JE, Chibnik LB, Maher NE, Matthews HM, Bilics JA, et al. Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol (2006) 33(7):1275-81
191. Löfvenborg JE, Andersson T, Carlsson P-O, Dorkhan M, Groop L, Martinell M, et al. Coffee consumption and the risk of latent autoimmune diabetes in adults-results from a Swedish case-control study. Diabet Med (2014) 31(7):799-805. doi:10.1111/dme.12469
192. Virtanen SM, Uusitalo L, Kenward MG, Nevalainen J, Uusitalo U, Kronberg-Kippilä C, et al. Maternal food consumption during pregnancy and risk of advanced β-cell autoimmunity in the offspring. Pediatr Diabetes (2011) 12(2):95-9. doi:10.1111/j.1399-5448.2010.00668.x
193. Lammert C, Juran BD, Schlicht E, Xie X, Atkinson EJ, de Andrade M, et al. Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis. Clin Gastroenterol Hepatol (2014) 12(9):1562-8. doi:10.1016/j.cgh.2013.12.036
194. Andersen IM, Tengesdal G, Lie BA, Boberg KM, Karlsen TH, Hov JR. Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2014) 12(6):1019-28. doi:10.1016/j.cgh.2013.09.024
195. Nobles J, Weintraub MR, Adler NE. Subjective socioeconomic status and health: relationships reconsidered. Soc Sci Med (2013) 82:58-66. doi:10.1016/j.socscimed.2013.01.021
196. Okada H, Kuhn C, Feillet H, Bach JF. The "hygiene hypothesis" for autoimmune and allergic diseases: an update. Clin Exp Immunol (2010) 160(1):1-9. doi:10.1111/j.1365-2249.2010.04139.x
197. Reckner Olsson A, Skogh T, Wingren G. Comorbidity and lifestyle, reproductive factors, and environmental exposures associated with rheumatoid arthritis. Ann Rheum Dis (2001) 60(10):934-9. doi:10.1136/ard.60.10.934
198. Wolfe F, Michaud K. Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum (2009) 61(11):1563-70. doi:10.1002/art.24724
199. Calixto OJ, Anaya JM. Socioeconomic status. The relationship with health and autoimmune diseases. Autoimmun Rev (2014) 13(6):641-54. doi:10.1016/j.autrev.2013.12.002
200. Callahan LF, Pincus T. Formal education level as a significant marker of clinical status in rheumatoid arthritis. Arthritis Rheum (1988) 31(11):1346-57. doi:10.1002/art.1780311102
201. Bengtsson C, Nordmark B, Klareskog L, Lundberg I, Alfredsson L; EIRA Study Group. Socioeconomic status and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis (2005) 64(11):1588-94. doi:10.1136/ard.2004.031666
202. Groessl EJ, Ganiats TG, Sarkin AJ. Sociodemographic differences in quality of life in rheumatoid arthritis. Pharmacoeconomics (2006) 24(2):109-21. doi:10.2165/00019053-200624020-00002
203. Brekke M, Hjortdahl P, Thelle DS, Kvien TK. Disease activity and severity in patients with rheumatoid arthritis: relations to socioeconomic inequality. Soc Sci Med (1999) 48(12):1743-50. doi:10.1016/S0277-9536(99)00075-1
204. Uhlig T. Which patients with rheumatoid arthritis are still working? Arthritis Res Ther (2010) 12(2):114. doi:10.1186/ar2979
205. Molina E, del Rincon I, Restrepo JF, Battafarano DF, Escalante A. Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis. Arthritis Care Res (Hoboken) (2015) 67(7):940-6. doi:10.1002/acr.22542
206. Chen C, Huang K, Wang J, Huang H, Chou P, Lee C. Combined effect of individual and neighbourhood socioeconomic status on mortality of rheumatoid arthritis patients under universal health care coverage system. Fam Pract (2015) 32(1):41-8. doi:10.1093/fampra/cmu059
207. Zhu TY, Tam LS, Li EK. Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) (2011) 63(5):751-60. doi:10.1002/acr.20410
208. Mendoza-Pinto C, Méndez-Martínez S, Soto-Santillán P, Galindo Herrera J, Pérez-Contreras I, Macías-Díaz S, et al. Socioeconomic status and organ damage in Mexican systemic lupus erythematosus women. Lupus (2015) 24(11):1227-32. doi:10.1177/0961203315591621
209. Maynard JW, Fang H, Petri M. Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosus. J Rheumatol (2012) 39(4):777-83. doi:10.3899/jrheum.110724
210. Minden SL, Hoaglin DC, Hadden L, Frankel D, Robbins T, Perloff J. Access to and utilization of neurologists by people with multiple sclerosis. Neurology (2008) 70(13 Pt 2):1141-9. doi:10.1212/01.wnl.0000306411.46934.ef
211. Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, Chakravorty BJ, Tyry T, Moreau RL, et al. Comparisons of Latinos, African Americans, and Caucasians with multiple sclerosis. Ethn Dis (2010) 20(4):451-7
212. Hughes GC, Choubey D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat Rev Rheumatol (2014) 10(12):740-51. doi:10.1038/nrrheum.2014.144
213. Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun (2012) 38(2-3):J109-19. doi:10.1016/j.jaut.2011.10.003
214. Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther (2009) 11(5):252. doi:10.1186/ar2825
215. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med (2005) 353(24):2539-49. doi:10.1056/NEJMoa050817
216. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med (2005) 353(24):2550-8. doi:10.1056/NEJMoa051135
217. Rojas-Villarraga A, Torres-Gonzalez J-V, Ruiz-Sternberg Á-M. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis. PLoS One (2014) 9(8):e104303. doi:10.1371/journal.pone.0104303
218. Qi S, Xin R, Guo W, Liu Y. Meta-analysis of oral contraceptives and rheumatoid arthritis risk in women. Ther Clin Risk Manag (2014) 10:915-23. doi:10.2147/TCRM.S70867
219. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren's syndrome. Autoimmun Rev (2010) 9(5):A305-10. doi:10.1016/j.autrev.2009.11.004
220. Molina R, Provost TT, Arnett FC, Bias WB, Hochberg MC, Wilson RW, et al. Primary Sjögren's syndrome in men. Clinical, serologic, and immunogenetic features. Am J Med (1986) 80(1):23-31. doi:10.1016/0002-9343(86)90044-6
221. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) (2009) 88(5):284-93. doi:10.1097/MD.0b013e3181b76ab5
222. Anaya JM, McGuff HS, Banks PM, Talal N. Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome. Semin Arthritis Rheum (1996) 25(5):337-46. doi:10.1016/S0049-0172(96)80019-9
223. Krassas G, Karras SN, Pontikides N. Thyroid diseases during pregnancy: a number of important issues. Hormones (Athens) (2015) 14(1):59-69
224. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya J-M. Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis (2012) 2012:254319. doi:10.1155/2012/254319
225. Marrosu MG, Cocco E, Lai M, Spinicci G, Pischedda MP, Contu P. Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet (2002) 359(9316):1461-5. doi:10.1016/S0140-6736(02)08431-3
226. Handel AE, Handunnetthi L, Ebers GC, Ramagopalan SV. Type 1 diabetes mellitus and multiple sclerosis: common etiological features. Nat Rev Endocrinol (2009) 5(12):655-64. doi:10.1038/nrendo.2009.216
227. Demirezer Bolat A, Akin FE, Tahtaci M, Tayfur Yürekli Ö, Köseoglu H, Erten S, et al. Risk factors for polyautoimmunity among patients with celiac disease: a cross-sectional survey. Digestion (2015) 92(4):185-91. doi:10.1159/000439586
228. Ota K, Dambaeva S, Han AR, Beaman K, Gilman-Sachs A, Kwak-Kim J. Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity. Hum Reprod (2014) 29(2):208-19. doi:10.1093/humrep/det424
229. Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis (2011) 70(1):145-50. doi:10.1136/ard.2010.134817
230. Schoindre Y, Jallouli M, Tanguy ML, Ghillani P, Galicier L, Aumaitre O, et al. Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. Lupus Sci Med (2014) 1(1):e000027. doi:10.1136/lupus-2014-000027
231. Schneider L, Colar AC, Werres Junior LC, Alegretti AP, Pereira AS, Santos M, et al. Vitamin D levels and cytokine profiles in patients with systemic lupus erythematosus. Lupus (2015) 24(11):1191-7. doi:10.1177/0961203315584811
232. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis (2007) 66(9):1137-42. doi:10.1136/ard.2007.069831
233. Gustafsson JT, Gunnarsson I, Källberg H, Pettersson S, Zickert A, Vikerfors A, et al. Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus. Ann Rheum Dis (2014) 74(8):1537-43. doi:10.1136/annrheumdis-2013-205159
234. Fernández-Nebro A, Rúa-Figueroa Í, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, et al. Cardiovascular events in systemic lupus erythematosus. Medicine (Baltimore) (2015) 94(29):e1183. doi:10.1097/MD.0000000000001183
235. Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) (2007) 46(6):983-8. doi:10.1093/rheumatology/kem002
236. Calvo-Alén J, Toloza SM, Fernández M, Bastian HM, Fessler BJ, Roseman JM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum (2005) 52(7):2060-8. doi:10.1002/art.21149
237. Franco JS, Amaya-Amaya J, Molano-González N, Caro-Moreno J, Rodríguez-Jiménez M, Acosta-Ampudia Y, et al. Autoimmune thyroid disease in Colombian patients with systemic lupus erythematosus. Clin Endocrinol (Oxf) (2015) 83(6):943-50. doi:10.1111/cen.12662
238. Amador-Patarroyo MJ, Arbelaez JG, Mantilla RD, Rodriguez-Rodriguez A, Cárdenas-Roldán J, Pineda-Tamayo R, et al. Sjögren's syndrome at the crossroad of polyautoimmunity. J Autoimmun (2012) 39(3):199-205. doi:10.1016/j.jaut.2012.05.008
239. Anaya JM, Molano-González N, Rodríguez-Jiménez M, Amaya-Amaya J, Acosta-Ampudia J, Reyes-Beltran B, et al. Polyautoimmunity and familial autoimmunity in rheumatoid arthritis. Ann Rheum Dis (2015) 74(Suppl 2):249. doi:10.1136/annrheumdis-2015-eular.4165
240. Anaya J, Amaya-Amaya J, Amador-Patarroyo MJ, Herrera-Diaz C, Quintero OL, Cardenas-Roldan J, et al. Influence of low socioeconomic status on autoimmune rheumatic diseases. Ann Rheum Dis (2012) 71(Suppl 3):714. doi:10.1136/annrheumdis-2012-eular.1341
241. Cárdenas Roldán J, Amaya-Amaya J, Castellanos-de la Hoz J, Giraldo-Villamil J, Montoya-Ortiz G, Cruz-Tapias P, et al. Autoimmune thyroid disease in rheumatoid arthritis: a global perspective. Arthritis (2012) 2012:864907. doi:10.1155/2012/864907
242. Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya J, Shoenfeld Y. Epstein Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci (2007) 1108(1):567-77. doi:10.1196/annals.1422.059
243. Kivity S, Arango MT, Ehrenfeld M, Tehori O, Shoenfeld Y, Anaya JM, et al. Infection and autoimmunity in Sjogren's syndrome: a clinical study and comprehensive review. J Autoimmun (2014) 51:17-22. doi:10.1016/j.jaut.2014.02.008
244. Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, Blank M, Ram M, et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci (2009) 1173(1):658-63. doi:10.1111/j.1749-6632.2009.04754.x
245. Root-Bernstein R, Fairweather D. Complexities in the relationship between infection and autoimmunity. Curr Allergy Asthma Rep (2014) 14(1):407. doi:10.1007/s11882-013-0407-3
246. Barragán-Martínez C, Speck-Hernández CA, Montoya-Ortiz G, Mantilla RD, Anaya JM, Rojas-Villarraga A. Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis. PLoS One (2012) 7(12):e51506. doi:10.1371/journal.pone.0051506
247. Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol (2015) 14(3):263-73. doi:10.1016/S1474-4422(14)70267-4
248. Hedstrom A, Hillert J, Olsson T, Alfredsson L. Exposure to anaesthetic agents does not affect multiple sclerosis risk. Eur J Neurol (2013) 20:735-9. doi:10.1111/ene.12098
249. Valery P, Lucas R, Williams D, Pender MP, Chapman C, Coulthard A, et al. Occupational exposure and risk of central nervous system demyelination. Am J Epidemiol (2013) 177(9):954-61. doi:10.1093/aje/kws361
250. Horwitz H, Ahlgren B, Naerum E. Effect of occupation on risk of developing MS: an insurance cohort study. BMJ Open (2013) 3:e002894. doi:10.1136/bmjopen-2013-002894
251. Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS. Physical and social environment and the risk of multiple sclerosis. Mult Scler Relat Disord (2014) 3:600-6. doi:10.1016/j.msard.2014.07.002
252. Marie I, Gehanno JF, Bubenheim M, Duval-Modeste AB, Joly P, Dominique S, et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev (2014) 13(2):151-6. doi:10.1016/j.autrev.2013.10.002
253. Marie I, Menard J-F, Duval-Modeste AB, Joly P, Dominique S, Bravard P, et al. Association of occupational exposure with features of systemic sclerosis. J Am Acad Dermatol (2015) 72(3):456-64. doi:10.1016/j.jaad.2014.11.027
254. Marie I. Systemic sclerosis and occupational exposure: towards an extension of legal recognition as occupational disorder in 2014? La Rev médecine interne (2014) 35(10):631-5. doi:10.1016/j.revmed.2014.04.002
255. Li X, Sundquist J, Sundquist K, Zoller B. Occupational risk factors for systemic lupus erythematosus: a nationwide study based on hospitalizations in Sweden. J Rheumatol (2012) 39(4):743-51. doi:10.3899/jrheum.110789
256. Castiblanco J, Anaya JM. Genetics and vaccines in the era of personalized medicine. Curr Genomics (2015) 16(1):47-59. doi:10.2174/1389202916666141223220551
257. Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res (2015) 100:190-209. doi:10.1016/j.phrs.2015.08.003
258. Hawkes D, Benhamu J, Sidwell T, Miles R, Dunlop RA. Revisiting adverse reactions to vaccines: a critical appraisal of autoimmune syndrome induced by adjuvants (ASIA). J Autoimmun (2015) 59:77-84. doi:10.1016/j.jaut.2015.02.005
259. Anaya JM, Reyes B, Perdomo-Arciniegas AM, Camacho-Rodríguez B, Rojas-Villarraga A. Autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine. Clin Exp Rheumatol (2015) 33(4):545-8
260. Ahmed SS, Schur PH, MacDonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun (2014) 50:1-11. doi:10.1016/j.jaut.2014.01.033
261. Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med (2015) 7(294):294ra105. doi:10.1126/scitranslmed.aab2354
262. De Martino M, Chiappini E, Galli L. Vaccines and autoimmunity. Int J Immunopathol Pharmacol (2013) 26(2):283-90
263. Mercado U. Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus? J Rheumatol (2006) 33(8):1469-71
264. McKinnon JE, Maksimowicz-McKinnon K. Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications. Transl Res (2015) 167(1):46-60. doi:10.1016/j.trsl.2015.08.008
265. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran M, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2011) 70(3):414-22. doi:10.1136/ard.2010.137216
266. Castiblanco J, Arcos-Burgos M, Anaya JM. What is next after the genes for autoimmunity? BMC Med (2013) 11:197. doi:10.1186/1741-7015-11-197
267. Carlsten C, Brauer M, Brinkman F, Brook J, Daley D, McNagny K, et al. Genes, the environment and personalized medicine: we need to harness both environmental and genetic data to maximize personal and population health. EMBO Rep (2014) 15(7):736-9. doi:10.15252/embr.201438480